Evidence map›Paper›PMID 41758044›Full record

ArticleHepatology communications2026

Low anti-Mullerian hormone in reproductive age is associated with MASLD in midlife.

Katherine M Cooper, Melissa Wellons, James G Terry, Heather G Huddleston, Marcelle I Cedars, Stephanie S Maldonado, Monika Sarkar

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Katherine M CooperDepartment of Medicine, UMass Chan Medical School, Worcester, Massachusetts, USA.ORCID 0000-0002-6030-4773
Melissa WellonsDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
James G TerryDepartment of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Heather G HuddlestonDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, California, USA.
Marcelle I CedarsDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, California, USA.
Stephanie S MaldonadoDepartment of Medicine, Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, California, USA.
Monika SarkarDepartment of Medicine, Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-Mullerian hormone (AMH) is produced by ovarian follicles and is clinically reflective of reproductive aging. AMH has been associated with the severity of steatohepatitis in those with known metabolic dysfunction-associated steatotic liver disease (MASLD), although its association with prevalent MASLD is not known.

methodsUsing the multicenter longitudinal Coronary Artery Risk Development in Young Adults cohort, we evaluated the association of low AMH levels in healthy young women with subsequent MASLD in midlife, assessed by CT scan 10 years later. Alternate causes of steatosis were excluded, and multivariable logistic regression was adjusted for confounding metabolic risk factors.

resultsAmong 585 eligible participants, 50 (8.5%) had MASLD. MASLD was more common among participants with low AMH (14% vs. 7%, p=0.03). Adjusted for baseline covariates, low AMH was associated with 2.50-fold higher odds of prevalent MASLD (95% CI: 1.18-5.28, p=0.02). The findings persisted after adjusting for both baseline and change in metabolic profiles (OR: 2.36, 95% CI: 1.05-5.27, p=0.04). The relationship between low AMH and MASLD was not mediated by body mass index (p=0.82) or visceral adipose tissue volume (p=0.14).

conclusionsLow AMH levels in reproductive-aged women conferred a more than 2-fold higher odds of prevalent MASLD in midlife, independent of metabolic comorbidities. AMH levels may therefore serve as a valuable marker of MASLD risk in young women.

Indexed as

Anti-Mullerian HormoneFatty LiverAdultBiomarkersFemaleHumansLongitudinal StudiesMiddle AgedPrevalenceRisk FactorsAnti-Mullerian HormoneBiomarkersagingchronic liver diseasecirrhosismenopausereproductive health

Identifiers

PMID41758044
PMCPMC12947985

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.